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1CHAPTER 1. INTRODUCTION
Glucocorticosteroids are a class of steroids that have been used to obtain beneficial
and detrimental results in the horse and dog racing industry. Glucocorticosteroids, also
known as glucocorticoids, are used to treat inflammation in horses and dogs that have been
stressed or injured to allow the animals to return to the racing circuit more quickly than
naturally. While these treatments, when used correctly, would benefit the animal just as
anti-inflammatories benefit humans, they can also cause detrimental effects to the health of
the animal.
Glucocorticoids are a key ingredient in maintaining homeostasis in the body. This
homeostasis is affected by trauma, exercise and cold that increase production of the
corticotropin releasing factor in the hypothalamus (Wilke et al 1982). The corticotropin
releasing factor increases the production of glucocorticoids (Wilke et al 1982).
There are two reasons for interest in the ability to detect glucocorticoids in racing
animals. First, glucocorticoid residuals in the animal are undesirable in the racing industry
as the residuals can be evidence of dosing the animal. Since these chemicals decrease the
amount of pain the animal experiences, the animal may increase trauma due to lack of
feedback. The decreased pain may be a result of reduced pressure on the nerves due to less
inflammation but the exact reason is unclear (Martindale, 2005). The second reason is that
the treatment with glucocorticoids can affect performance that could affect the outcome of
the pari-mutuel races. Pari-mutuel racing, dogs and horses, generated over $4 billion in
revenues and receipts in the United States in 2002 (U.S. Census Bureau 2002). 
This paper presents research to characterize and quantify glucocorticoids in equine
urine and plasma and in canine urine. This paper also summarizes an elimination study of
an under-examined glucocorticoid. The research incorporates a liquid\liquid extraction
from a small aliquot of sample. This aliquot is analyzed for many glucocorticoids in a
single liquid chromatography mass spectrometry run.
2CHAPTER 2. LITERATURE REVIEW
Cortisol (hydrocortisone) is the principal glucocorticoid in horse and dog blood and
also the most potent naturally produced corticosteroid (Gower, 1984). Cortisol is produced
by the adrenal gland, decreases the body’s response to stress, decreases inflammation, and
can cause euphoria. One study states the normal range in horses to be 50-3500 nmol/L
(Irvine et al 1988). Cortisol maintains homeostasis in the body. Introduction of
compounds that mimic cortisol decreases cortisol production (Toutain et al, 1984).
Synthesis: “The adrenal cortex produces corticosteroids which are a group of C21
steroids” (Gallciano, 1985). “This group known as 4-en-3-ones contains a double bond at
C-4 and an oxo group at C-3. These compounds also have a side chain at C-17 and may or
may not contain a hydroxyl group. The 17- hydroxylated glucocorticoids are more
powerful than the non-hydroxylated counterparts. There is hydroxyl at C-21 and an oxo
group at C-20.” “There also needs to be an oxygen function, hydroxyl or oxo group which
may or may not be at C-11” (Gower, 1984). The steroid numbering system is illustrated
using cortisol in figure 1.
Figure 1. Chemical structure of cortisol with steroid numbering system (Wilke, 1982)
3Effects: Gower (1984) stated corticosteroids increase blood glucose level by promoting
the hepatic conversion of amino acids to glucose. These compounds also oppose insulin in
allowing glucose into adipose cells, which in effect mobilizes fat and releases free fatty
acids to the liver. Corticosteroids cause a net reduction in protein synthesis in muscle and
lymphatic tissue, which reduces antibody synthesis. This net protein loss is due to
increased protein catabolism (Martindale, 2005). Deluca (1984) stated glucocorticoids also
suppress intestinal calcium absorption therefore lowering plasma calcium levels. Lower
plasma calcium levels can lead to bone decalcification.
Corticosteroids counteract the histamine and serotonin effects of increased capillary
permeability and dilation which are part of the inflammatory response. This increased
capillary resistance reduces the movement of leucocytes to the site of infection. Therefore,
phagocytosis decreases (Gower, 1984). These chemicals can also cause adrenal gland
atrophy (Ralston and Stenhouse, 1990).
Cholesterol is transformed by desmolase in the mitochondria to yield pregnenolone.
“This reaction includes two hydoxylases and utilizes cytochrome P450” (Garrett and
Grisham, 1999). The pregnenolone is transported to the endoplasmic reticulum and
converted into progesterone, which involves a hydroxyl oxidation and the double bond
being transferred to a different ring (Garrett and Grisham, 1999). The sequence is
diagramed in figure 2 on page 4.
Metabolites: There are four major pathways for steroid degradation: (Gower, 1984).
1. “Reduction of the double bond at c-4 with accompanying reduction of the C-3
oxo group to a secondary alcohol group.
2. Reduction of the C-20 oxo group to a secondary alcohol group.
3. Oxidation of the 17B-hydroxyl group.
4. Further hydroxylation at various points in the steroid nucleus.”
In addition, the corticosteroids can convert to carboxylic acid derivatives. The
majority of the corticosteroids are excreted as sulfate compounds or as glucuronide
compounds (Gower, 1984). Norman (2002) stated the principal conjugated product is
4glucuronides. Volin (1994) stated corticosteroids are excreted as sulphuric and glucoronic
acid compounds which are water-soluble.
Figure 2. Route from cholesterol to cortisol (Garrett and Grisham, 1999)
Some glucocorticoid metabolites in equine urine are described below.
Dexamethasone’s major metabolite is 9-fluoro-16 alpha-methyl-6 beta,11- beta, 16- beta
trihydroxy-1, 4- andostadiene-3,17-dione, M.W.=364 (Maylin and Skrabal, 1982).
Betamethasone’s main excretionary products in horses are betamethasone and 6-hydroxy
betamethasone (Rodchenkov, 1988). Methylprednisolone’s main metabolites are
methylprednisone, 20-dihydromethylprednisolone, 20-dihydromethylprednisone (Ralston
and Stenhouse, 1990), 17,21-dihydroxy-6alpha-methyl-1,4 pregnadiene-3,11,20-trione,
6alfa-methyl-17,20 beta,21-trihydroxy-1-4 pregnadiene-3,11 dione and 6 alpha –methyl-
11b,17,20 beta,21-tetrahydroxy-1,4 pregnadien-3-one (Gallciano et al,1985). Cortisol’s
main metabolites are 20-beta-dihydrocortisol (Popot et al,1996), (Sams,1996), 11-beta-
5hydroxyandrosterone (Popot et al,1994), 11-beta-hydroxyetiochlanolone (Popot et al,
1994), 20- beta dihydrocortisone (Popot et al, 1996) and cortisone (Popot et al, 1996). 
Some of these compounds are illustrated in Figure 3 on page 6.
Excretion: Tracking the excretion pharmacokinetics of steroids presents challenges. The
pH of horse urine varies widely and the pH affects excretion rates (Sams, 1996). The pH
of urine of a rested horse is about 8.4 while the plasma pH is about 7.4 (Sams, 1996). The
pH of equine urine can decrease to as low as 5.4 after exercise (Sams, 1996). Irvine et al
(1988) examined post race urine samples from 69 thoroughbred and 41 standard bred
horses and found a pH range of 5.3 to 9.6. Alkaline pH levels of urine, such as those in a
resting horse, can greatly increase excretion of the conjugated corticosteroids compared to
the excretion rates when the pH of the urine is more acidic than that of the blood (Sams,
1996).
Factors affecting glucocorticoid concentration: Many glucocorticoids are endogenous,
produced naturally by the body (Lewis, 1998). Therefore, an animal will constantly have
concentrations of these endogenous compounds in its system. This concentration level of
endogenous glucocorticoids is the baseline concentration level for that animal if the animal
is resting, not under stress and has not recently engaged in exercise.
Exogenous compounds are produced from outside the subject (Lewis, 1998).
These compounds can be those, which could be found naturally in the body, or they could
be synthesized compounds. Examples of endogenous and exogenous corticosteroids are in
table 1 on page 8.
Detection of doping with endogenous glucocorticoids is challenging due to
individual differences in baseline levels in the subjects. These parameters make litigation
against the abusers more difficult since the glucocorticoid levels must be proven to be
greater than normal baseline levels for that particular animal. This situation is complicated
further because levels of these substances can increase up to 50% in response to exercise
(McKenna, 1994).
6Figure 3. Dexamethasone and betamethasone with major metabolites
(Rodchenkov, 1988, Skrabalak, 1982)
Exercise and breed of horse affect glucocorticoid levels. A study of trotting horses
and standardbred horses gave an arithmetic mean post race cortisol level in serum of 71
ng/ml with a range of 39-141 ng/ml. The mean cortisol levels in these same horses at rest
were 31 +/- 2.1 ng/ml in the trotting horses. The range in the resting trotting horses was
724.3-37.8 ng/ml. The mean cortisol level in the resting standardbred horses was 19 +/- 2.6
ng/ml, with a range of 7.1- 41.3 ng/ml (Shultz et al, 1994).
Prescribed veterinary treatment of injuries can cause lingering drug effects. For
example, using 25 mg of prednisolone injected intratendinously can relieve pain (measured
as lameness) for 6 days. Prednisolone can be detected 16 days after treatment using
reversed phase High Pressure Liquid Chromatography (HPLC) and off-line detection with
immunoassay (Shultz, 1994).
Endogenous steroid suppression is the phenomenon of endogenous steroid
production decreasing due to the presence of an administered corticosteroid. Toutain et al
(1984) demonstrated this phenomenon by injecting different horses with various synthetic
glucocorticoids. This study demonstrated that after injection with dexamethasone the
cortisol concentrations in plasma were depressed for approximately four days. A
prednisolone injection depressed cortisol plasma concentrations for a period of nearly 21
days (Toutain et al, 1984).
Toutain et al (1983) demonstrated this effect in canine subjects. In an experiment
using five mixed breed dogs of both sexes, dexamethasone was given intravenously (IV) at
a dose of 1 mg/kg body weight or intramuscularly (IM) in either 0.1 or 1 mg/kg dose by
body weight. The compounds administered were dexamethasone alcohol and
dexamethasone 21-isonictinate solution and dexamethasone 21-isonictinate as a
suspension. The solutions, whether administered IV or IM, initially depressed cortisol
levels. These cortisol levels returned to baseline within 48 hours for the solutions. The
suspension depressed cortisol levels for 10 days in the 0.1 mg/kg test and one month in the
1 mg/kg test.
Some glucocorticoid concentration levels are affected by the route of
administration. Methylprednisolone can be used with intra-articular (inside joint cavity)
administration for relief of acute and long-term joint ailments. Methylprednisolone is
excreted more quickly when given intra-articularly than intra-muscularly (Ralston and
Stenhouse, 1990). Dexamethasone showed no difference in excretion rates due to route of
8administration (Dumsia, 1976). The horses in the various route of injecting
dexamethasone study were dosed intramuscularly or with an IV of dexamethasone ranging
in concentration from 40-85 ug/kg (Dumsia, 1976). Several glucocorticoids are listed in
table 1.
Table 1. List of various endogenous and exogenous glucocorticoids.
Chemical name M.W. Chemical formula Exogenous
amcinonide 502.6 C28H35FO7 y
betamethasone 392.5 C22H29FO5 y
clobetasol propionate 467.0 C25H32ClFO5 y
clocortolone pivalate 495.0 C27H36ClFO5 y
cloprednol 392.9 C21H25ClO5 y
cortisone 360.5 C21H28O5 n
cortivazol 530.7 C32H38N2O5 y
desoximethasone 376.5 C22H29FO4 y
dexamethasone 392.5 C22H29FO5 y
diflorasone diacetate 494.5 C26H32F2O7 y
diflucortolone valerate 478.6 C27H26F2O5 y
flucloronide 487.4 C24H29ClFO5 y
flumethasone pivalate 494.6 C27H36F2O6 y
fluocinolone acetonide 452.5 C24H30F2O6 y
fluocortolone 376.5 C22H29FO4 y
fluorometholone 376.5 C22H29FO4 y
fluprednisolone 378.4 C21H27FO5 y
flurandrenolide 436.5 C24H33FO6 y
formocortal 569.1 C29H38ClFO8 y
hydrocortamate hcl 512.1 C27H41NO6 -HCL y
hydrocortisone 362.5 C21H30O5 n
medrysone 344.5 C22H32O5 y
meprednisone 372.5 C22H28O5 y
prednisolone 360.4 C21H28O5 y
prednisone 358.4 C21H26O5 y
triamcinolone 394.4 C21H27FO6 y
Performance effects: In 1988, a study of 87 horses was conducted to determine the
influence of glucocorticoids on performance. The horses had been timed several times on
the same 5/8 mile track without corticosteroid injections. The results were averaged and
standard deviation calculated for each horse (Watrin, 1988). Varied amounts of
9dexamethasone (10-40 mg), flumethasone (5-10 mg) and prednisolone (75mg) were given
to test horses 2-8 hours prior to the race. They raced on the same track in the medicated
state as in the non-medicated trials. The route of administration was not mentioned in the
study. A measurable effect was defined as a difference of 1/5 of a second from the
subject’s average time. Of these 87 horses, 43% showed no effect to the drugs, 38%
showed an improvement in times and the remainders were measurably slower (Watrin,
1988). Unfortunately, the Watrin study did not state whether these horses were assessed
for pain prior to the races, which could account for these scattered results.
Soma et al (1998) compared equine responses to exercise after administration of
dexamethasone (0.05mg/kg), flunixin (1.1mg/kg) or saline (10 ml). The compounds were
administered intravenously. Dexamethasone was administered 12 hours prior to the tests.
The other compounds were administered two hours prior to exercise.
Heart rates were similar in all three tests groups after exercise on a treadmill.
Oxygen consumption and CO2 production were lower in the flunixin subjects than in the
other groups (Soma et al, 1988). Glucose levels increased in the dexamethasone group
compared to the other groups after exercise. Cortisol levels decreased in the
dexamethasone group and did not increase during exercise. This was not true with flunixin
or saline. Soma et al (1998) stated that the preliminary evidence showed that
dexamethasone and flunixin might influence the horse’s performance.
Chemical analysis: There are several methods for detecting corticosteroids in equine and
canine fluids. Immunoassay, Gas Chromatography/Mass Spectrometry (GC/MS), Thin
Layer Chromatography (TLC) and High Performance Liquid Chromatography / Mass
Spectrometry (HPLC/MS) appear to be the most common in the literature. These
techniques are used after the extraction\concentration process has been completed.
The extraction\concentration process reduces the volume of matrix to near zero.
This reduction of matrix volume concentrates the analytes of interest making detection and
quantification easier. This process also reduces or eliminates interfering compounds from
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the aliquot which will be analyzed. The extraction process was usually a liquid \liquid
extraction.
A liquid\liquid extraction for the purpose of extracting glucocorticoids from bodily
fluids involves adding an organic solvent, or extractant, to an aliquot of sample and mixing
the liquids together in a test tube. The organic solvent, during the mixing process, extracts
the organic components from the inorganic phase, which is mostly water and inorganic
salts.
The mixed sample is placed in a centrifuge to stratify the two phases, organic and
inorganic. The organic phase is carefully removed from the test tube with a Pasteur pipette
and placed into another clean test tube which is placed in an evaporator. The evaporator
contains a heated water bath and dispenses a stream of inert gas, usually nitrogen or
helium, into the tube to speed evaporation and prevent reactions with oxygen. After the
organic phase has evaporated, the test tube is removed from the evaporator. A small
amount of organic solvent, 100 ul or less is added to the tube to reconstitute the sample so
a representative aliquot of the sample can be analyzed.
Solid phase extraction involves adding the sample to a column which contains
beads coated with an organic compound. The sample is pulled by vacuum though the
column with the organic components of the sample adhering to the column. This column
may be rinsed with an inorganic solvent to eliminate inorganic compounds which may
have been retained in the column. An organic solvent is added to the column to rinse the
organic components from the sample into a test tube. This test tube is inserted into the
evaporator and reconstituted in an organic solvent. This sample is ready for analysis.
Gas Chromatography: Gas chromatography involves the separation and detection of
analytes in the gaseous state. A sample aliquot is injected into a heated port on the gas
chromatograph called an injector. The injector quickly volatilizes the liquid sample into a
gas. This gaseous sample is carried out of the injection port and through the gas
chromatography column by a carrier gas. The carrier gas is called the mobile phase and is
usually helium or nitrogen.
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The column has a thin organic interior coating. The coating is denoted as the
stationary phase. The column is contained in an oven that increases the temperature of the
column during the separation or run. This temperature increase is termed the temperature
gradient. As the gaseous sample passes though the column, it is absorbed into and out of
the stationary phase thousands of times prior to reaching the detector. This action
lengthens the amount of time the sample requires to travel from the injection port to the
detector. This length of time is called the retention time (RT).
The length of time for each adsorption and desorbtion cycle varies depending upon
the chemical composition of the analyte. Therefore, different analytes will have different
RTs. This time is characteristic of that analyte for that particular column coating, length
and diameter of column, thickness of column coating, type of column coating and
temperature gradient.
The analytes after extraction/concentration process are derivatized in order to be
heat stable and detectable in this method. The derivitization process adds a compound to
the molecule to improve its stability at elevated temperatures. This changes the mass to
charge ratio (m/z) of the analyte. The derivatization process can lead to a variety of end
products.
In an experiment to determine cortisol concentrations using methoxyamine-
trimethylsilyl (MO-triTMS) derivatives, the deuterated compounds yielded two different
compounds and were encapsulated in two different chromatographic peaks (Ralston,
1990). For an ideal derivitization, this process should yield one compound and therefore
one chromatographic peak. The splitting of the peaks reduces the peak area making
quantification more difficult. Obtaining two different compounds makes analyte
identification more difficult. The undeuterated cortisol had two chromatographic peaks
also, due to formation of both anti and syn isomers (Ralston, 1990).
Another experiment demonstrated varying amount of derivatized fractions
depending upon temperature used in the derivatization process (Rodchenkov, 1988). For
betamethasone, a derivitisation temperature of 80 0C for 3 hours yielded a mono-
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methoxyamine (MO) derivative. Derivitization overnight at 57 0C yielded a bi-
methoxyamine derivative. This experiment also demonstrated that betamethasone required
a more rigorous derivatization procedure than dexamethasone required. (Rodchenkov,
1988). Schnazner (1994) stated that steric hindrance created by the 9-fluoro group retards
derivitization of the 11- beta hydroxyl group.
Different derivatization agents provide different results for various glucocorticoids.
Schanzer et al (1994) reported on this phenomenon using N-methyl-N-trimethylsilyl-
trifluoroacetamide (MSTFA) to derivatize dexamethasone and betamethasone which
produced better results than MO-tri TMS. However, MO-triTMS worked better for
prednisolone and prednisone than MSTFA (Schanzer, 1994).
Mass spectrometry detection: Mass spectrometry can be divided into two different
ionization categories, hard and soft. Hard ionization involves adding a great deal of energy
to a molecule, which leads to fragmentation and possible rearrangement of the molecule.
Hard ionization processes leave little of the original molecule. Electron Impact (EI) is an
example of a hard ionization technique. Figure 4 illustrates this ionization technique.
Figure 4. Illustration of electron impact for molecule ABC (Crews, 1998)
[A-C]+ + B
[A-C]+. + B
[A-C] . + B [A]+ + [C]+




[A-B-C] + e- 2e-
12
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Figure 4 illustrates molecule ABC being ionized by one electron that also displaces
an electron from the molecule. This molecule either fragments such as in path 1 or
rearranges and then fragments as in path 2.
Chemical Ionization (CI) is an example of a soft ionization technique. This
technique ionizes a reagent gas such as methane or ammonia and this gas reacts with the
analyte to create an ion of the analyte and heat. This process is outlined in figure 5.
Figure 5. Diagram of chemical ionization reactions (Crews, 1998)
In figure 5, the reagent gas is denoted as Y and the analyte as M. Soft ionization
techniques also produce molecular fragments that aid in identifying compounds of
identical molecular weights since different compounds will exhibit different fragmentation
patterns.
The use of CI leads to more certain identification spectra than EI using the M+1
weight (Signh et al, 1989). Singh et al analyzed 17 different steroid compounds, including
metabolites, using CI and EI with GC/MS. Using EI, the base peak of 13 of these
compounds was m/z 73. This fragment is the trimethylsilyl from the derivitization agent N,
O-bis (trimethylsilyl) trifluoroacetamide (BSTFA). A base peak is the largest m/z peak in
the mass spectra. There were five base peaks for the 17 compounds (Signh et al, 1989). 
The CI had 12 different base peaks for the 17 compounds, which allows for easier
identification than the 5 base peaks in EI. Two testosterone metabolites were not detected
with CI. The reason these peaks were not detected was not stated. There also were two
pairs of isomers in the group. The EI yielded peak ratio intensities that could be used for
identification between alpha and beta-cortol and alpha-cortolone and beta- cortolone. The
CI peak ratio intensities for the cortolone isomers could be used for identification. The
peak intensity ratios for the cortol isomers were identical for CI (Signh et al, 1989).  
YH+n +M YH n-1 +MH+ +  H
Y- + M YH + [M+H]- +  H
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Thin layer chromatography (TLC): Thin layer chromatography is a useful technique in a
qualitative sense, but in a quantitative use, it is subjective. This technique involves placing
an aliquot of extracted sample near the bottom edge of a coated plate. This plate is placed
nearly vertical in a volume of eluting solvent. The eluting solvent is absorbed up the plate
moving the analyte up the plate as well. The plate is removed from the eluting solvent
before the eluting solvent reaches the top of the plate. The position of the eluting solvent
is marked.
The plate is dried and sprayed with various dyes. The analyte and dye
combination will produce different colors depending upon the analyte. The color intensity
of the dye analyte combination correlates to analyte concentration. The ratio of distance
the analyte traveled divide by the distance the eluting solvent traveled is characteristic of
the analyte. This ratio is defined as the retardation factor, Rf (Skoog, 1985).
This technique qualifies compounds by the distance the compound travels up a
plate carried by the eluting solvent and by the color produced when sprayed with different
dyes. The subjectivity in this method is due to the experimenters quantifying the color
intensity, which corresponds to analyte concentration (Fritz and Shenk, 1987).
The analyte dye combination may absorb ultraviolet (UV) light which produces
dark spots on the plate when viewed under UV light. This phenomenon defined as
quenching is characteristic of some compounds. The analyte dye combination may also
fluoresce, which is characteristic of other compounds.
Gallicano et al (1985) performed an experiment using thin layer chromatography as
a qualitative tool for separating methylprednisolone and its metabolites. The solvent
system used was 9:1(v/v) chloroform/methanol with 0.25 mm precoated silica gel 60 F-254
plates. The compounds were located by the observance of fluorescence or quenching of
UV 254 light. After spraying the plate with phosphotungstic acid (PTA) spray reagent
(15%w/v in ethanol), some compounds yielded a yellow color. Spraying the plate with
tetrazolium blue (TZB) (0.07%w/v in 1:2v/v of ethanol/ 10% NaOH) turns some
compounds purple. For example, methylprednisolone in this experiment reacted with both
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dyes. Methyprednisone only reacted with TZB. The TZB reacts with the alpha – ketol
group, however, a reduced c-20 keto group prevents color formation. The Rf values
(methyprednisolone Rf = 0.37, methyprednisone Rf = 0.54) along with the spray results
allowed compound identification. These plates were not used for quantification (Gallicano
et al, 1985).  
Enzyme-Linked ImmunoSorbent Assay (ELISA): ELISA is an assay that uses
antibodies and enzymes to create a complex that affects color concentration in proportion
to the concentration of the analyte (Lewis, 1998). ELISA is a technique that has low
detection limits for many drugs. For example, d, l- methadone can be detected at 0.05 ng
per ml of urine or 1pg /well. This technique has a range up to 125 pg/well with a
1:100,000-antiserum titre.
One of the problems with ELISA screening, however, is false suspicious (cross
reactivity) results. In this instance, if d, l-methadone has a nominal value of 100%, the
cross reactivity was 42% for l-methadone, 84% for d-methadone and 450% for alpha, beta-
d, methadol –hemisuccinate. The cross reactivity for other corticoids such as codeine and
morphine was < 0.01% (Schultz et al, 1998). A current manufacturer of dexamethasone
ELISA kits lists cross-reactivities for prednisolone = 42.6%, isoflupredone = 27.8 % and
triacinolone =10% (Bio-X Diagnostics, 2005).
Dexamethasone had a detection range in an ELISA experiment from 0.01 ng/ml to
50 ug/ml. The cross reactivity with flumethasone however was 100 % (Zhu et al, 1992).
Anti-sera from treated rabbits were used to develop this test. Three mares that were
injected with 5 mg of dexamethasone had their urine, serum and plasma analyzed for this
study. Dexamethasone was detectable for 1 week in the urine.
Another drawback to ELISA testing is that some drugs may not be detected if the
correct test battery is not selected. This makes prescreening of samples prior to ELISA
useful, but does require extra time and resources.
Liquid Chromatography using Mass Spectrometry detection (LC/MS): Liquid
chromatography involves separating liquid analytes with a liquid chromatography column.
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The liquid sample is injected into liquid stream denoted as the mobile phase. The mobile
phase and sample are pumped into a liquid chromatography column. This column is
packed with particles that are coated with an organic substrate. The coating on these
particles is the stationary phase. Similar to gas chromatography, the analyte is absorbed
and desorbed from the stationary phase as it passes through the column. This process
lengthens the time for the analyte to transverse the column, leading to a retention time for
that particular analyte.
Liquid chromatography’s principle advantage over gas chromatography is that
samples do not need to be derivatized. This prevents formation of various derivatized
compounds from one analyte, which allows for less ambiguity in the analysis.
LC/MS in the past had been criticized as not being sensitive enough to detect very
low levels of corticosteroids. However, improvements in LC/MS and the use of tandem
MS has greatly improved these detection limits. Mass spectrometry to the nth power
(MSn) allows for more specificity. Parent ions fragment in unique patterns in the mass
spectrometer. The fragment ions (daughters) of the parent ion lead to a more certain
identity when dealing with larger numbers of analytes.
Detection limits have improved greatly in recent years. In 1994, Samuels et al
detected 10 ng/ml of hydrocortisone in horse urine. A later study detected hydrocortisone
and cortisone at 2 ng/ml using Liquid Chromatography with tandem Mass Spectrometry
detection (LC/MS/MS) (Taylor et al, 2002). One of the main problems of LC/MS is
isolating individual peaks from each other when many different substances are in a given
sample.
Atmospheric Pressure Chemical Ionization (APCI) is an ionization technique that is
less dependent on buffers and buffer strength than other ionization techniques. APCI and
ElectroSpray Ionization (ESI) are classified as soft ionization techniques. Molecular
weight data can be obtained using soft techniques such as APCI and ESI. APCI is better
than ESI with non-polar compounds such as steroids. Electrospray Ionization (ESI) is
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better for more polar compounds (Thermo Electron Corp, 2003). The mechanism of the
APCI technique is diagrammed below.
 N2 +e- N2+. + 2e-
 N2. + H2O N2+ + H2O+.
 H2O+. + H2O H3O+ + HO.
 H3O+ + M (M+H)+ + H2O (Thermo Electron Corp, 2003)
Summary of literature review: Glucocorticoids in the body are produced in the adrenal
gland to maintain homeostasis. Glucocorticoids introduced into a subject from an outside
source can cause health problems such as adrenal gland atrophy and decreased disease
resistance for the subject as well as depress cortisol levels in the individual. These
compounds can also have therapeutic effects for the animal such as reduced inflammation
and pain. Glucocorticoid compounds can affect the athletic performance of animals, which
could cause individuals to dose animals with these compounds to profit in pari-mutuel
races.
Various techniques have been used throughout the years to identify and quantify
glucocorticoids. Many of these techniques are being replaced by less subjective although
more expensive diagnostic procedures. These newer techniques have lower detection
limits and are a more legally defensible procedure than the procedures the industry has
relied upon in the past.
Introduction to research project: This research project developed an analytical
procedure for qualification and quantification of glucocorticoids in different matrices in
equine plasma and urine as well as canine urine. The liquid\ liquid extraction is a variation
of an extraction done by Luo et al (2005). Experimentation with this extraction involved
pH adjustment and sample to solvent ratio changes. The analytical technique utilizes
LC/MSn with an APCI probe. Definitions are provided for standard calibration curve and
internal standard calibration.
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Drug elimination studies were performed to test the method. The elimination
studies provide data on the concentration of analytes in the urine and the speed the
compounds are eliminated from the body. Elimination studies using dexamethasone were
performed using canine and equine subjects. A fludrocortisone elimination study was
performed utilizing a canine subject.
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CHAPTER 3. METHODS AND MATERIALS
The following reagents and equipment were utilized to conduct this research.
Reagents:
MTBE: Fisher HPLC Grade
Methanol: Fisher HPLC Grade
Acetonitrile: Fisher HPLC Grade
Formic acid: Fisher 88%, certified ACS grade
Type 1 water: MilliQ Water System (Millipore) 18 megaohm reagent water.
Ammonium Formate: Fisher Lot # 046776
Hydrochloric acid: Fisher certified ACS plus
Ammonium hydroxide: Fisher certified ACS
6-alpha methylprednisololone: Sigma M0639 Lot # 107F-800
16-Beta methylprednisone: Steraloids P05800-000Batch # 6591
20-dihydro-6-alpha-methyprednisolone: synthesized from Sigma M-o639 Lot# 107F-0800
Amcinonide: SigmaA2428 Lot 079F0936
Beclomethasone: Sigma T-1643 Lot #24F-5950
Betamethasone: Sigma Lot# 126F0384
Clobetasone butyrate: Sigma C5548 Lot # 080H0759
Corticosterone: Sigma C2505 Lot# 016K1300
Cortisone: Sigma C2755 Lot #063K3517
Deoxycorticosterone: Steraloids Q3460-000 Batch # L1804
Desoxymethasone: Sigma D6038 Lot#025K1047
Dexamethasone: Sigma D9184 Lot# 036K1031
Dichlorasone acetate: Sigma D-6163 Lot # 100H0445
Fluadrenolide: Sigma F1642 Lot# 079F0708
Flucinonide: Sigma R 201596 Lot# C26H32F207
Fludrocortisone: Steraloids Q1280-000 Batch # B0255
Flumethasone: Sigma F-9507 Lot # 116F-0481
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Fluocinolone acetonide: Sigma F8880 Lot# 043K1167
Fluorometholone: Sigma Lot# 109F0549
Hydrocortisone: Sigma H-4001 Lot #38F-0863
Medrysone: Sigma M0388 Lot# 058F02711
Paramethasone acetate: USPC Lot # F-1 
Prednisolone: Sigma P-6004 Lot # 68F0511
Prednisone: Sigma P-6254 Lot # 117F-0426
Triamicinolone: Sigma T-1518 Lot# 24F-5955
Triamicinolone acetamide: Sigma T-1643 Lot # 24F-5950
Extraction equipment:
pH meter: Omega pH meter model # pHb-115
Rotorap: Bellco cell production roller apparatus. Range 0- 4 rpm. This device
continuously mixes racks of test tubes by inverting the racks on a set of rollers.
Centrifuge: IEC Centra-8. Separates liquids by density though centrifugal force.
Evaporator: Zymark turbovap LV evaporator.
Pipettes: Fisher glass Pastuer pipettes 5¾ in.
Pipette: Gilson 1 ml pipetman
Pipette: Eppendorf 10-100 ul reference pipette
Vortex apparatus: Fisher Vortex Genie 2, cat # 12-812
Test tubes for evaporation: Fisher 16mm X 100 mm
Screw top tubes: 16mm x 125mm. 10 ml or larger capacity.
Analytical instrumentation:
Column: Zorbax SB C8 3.5u 3.0 mm X 15 cm P/N 863954.306
HPLC: Agilient 1100 with degasser and autosampler. The degasser eliminates dissolved
gases making analysis more reproducible and more sensitive.
Column heater: Phenomenex HPLC column heater Thermasphere TS 130
Mass Spec: Finnagan LTQ
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HPLC mobile phase and diluent
HPLC mobile Phase A: 0.1 % Formic acid in H2O
B: 0.1 % Formic acid in Acetonitrile
Diluent: Combine 40 ml of 2 mM of ammonium formate in type 1 water with 60 ml of
methanol.
Standard calibration curve: A standard calibration curve is composed of aliquots of a
blank matrix that contain differing amounts of the desired analyte in increasing
concentration. These calibration samples are extracted and analyzed using the same
procedures used for the actual samples. The analyte areas are compared to the known
concentrations using linear regression in the case of a linear calibration curve. This linear
regression will produce a formula for the line computed for the standard concentration and
corresponding areas. The analyte areas for each sample are incorporated into the equation
that calculates the concentration of the analyte in the unknown sample.
Internal standard calibration: The internal standard should be chemically similar to the
analytes so the extraction process will produce similar recoveries between the internal
standard and the analytes. This similarity will also yield retention times that will be within
the run time of the analysis. The internal standard cannot be a substance that would be
contained in the sample.
Desoximethasone is the internal standard used for these studies. The internal
standard is added to the standards and samples at the beginning of the extraction process.
The aliquots of internal standard which are added to the standards and samples are the
same concentration and therefore the same volume is added to each sample and standard.
The peak areas of the internal standard should be similar after extraction in the
standards and samples. The internal standard areas in the calibration curve are averaged to
produce a benchmark area that is compared to the internal standard peak areas in the
samples. The internal standard area average of the calibration curve and the internal
standard area of the sample are converted to a ratio (calibration standard internal standard
area /sample internal standard average area). This ratio is multiplied by the concentration
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of the desired analyte calculated using the standard curve for that analyte. The internal
standard calibration corrects inconsistencies in several areas.
The first area of the analytical procedure that the internal standard calibration can
correct is in the extraction process. If the extraction process yielded lower or higher
recoveries for all of the analytes including the internal standard, all of the samples would
be corrected for that percent difference. Such recovery problems can be caused by
contamination, poor solvent quality or incorrect pipette settings when the sample is
reconstituted after the turbovap evaporation step.
The second area that internal calibration can correct is errors in the analytical run.
Problems such as incorrect sample volume uptake and changes in instrument temperatures
or pressures or ionization parameters can be corrected or at the very least detected, so the
problem can be corrected. Since the analyst would be aware of the area counts of the
internal standard and the retention time of the internal standard, the erroneous instrument
parameters can be corrected after the first sample of the run if the parameters are suspect.
This knowledge also helps detect eluent flow rate changes from previous runs due to
different tubing or column configuration.
Extraction procedure benefits: The extraction procedure eliminates the matrix of the
sample and concentrates the analytes in the sample. This improves detection by
eliminating compounds that create high background noise. High background noise could
make detection of the desired analyte more difficult or impossible. Extraction also
improves detection by increasing the concentration of the desired analytes, increasing the
analyte areas. This improves the signal to noise ratio for that peak which improves
quantification and identification.
The extraction procedure reduces the number of times the instrument needs to be
cleaned by eliminating much of the matrix which can contaminate interior components.
This lack of matrix leads to more consistent instrument performance. Analyzing extracted
samples, as opposed to non-extracted samples, increases instrument component lifetime
since these components need cleaning less frequently.
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The pH of the sample matrix needs to be optimized for urine and plasma samples
to optimize recovery of the analytes. This adjustment makes the analytes less water soluble
and easier to extract. The pH of the samples was adjusted using 50% ammonium
hydroxide or 3N HCl. Four analytes were selected that were representative of the group of
corticosteroids to be analyzed. These analytes, prednisone, betamethasone, dexamethasone
and dichlorisone acetate span the range of retention times and molecular weights in the
run.
Once the pH was determined, variations of the extract were performed. Type 1
water was added to an aliquot of sample to improve the extraction recovery by lowering
the salt concentration in the inorganic phase. This involved adding one milliliter of type 1
reagent water to the one milliliter of sample prior to extraction but after pH adjustment.
Another variation involved increasing the amount of Methyl-tert Butyl Ether (MTBE) from
5 ml to 7 ml with the water added to use with 1 ml of sample.
Internal standard preparation: A 1 ug/ul stock standard of desoximethasone was made
using powdered desoximethasone and reagent grade methanol. This standard was diluted
to 10 ng/ul for use as the internal standard.
Stock and working standard preparation: Stock standards of 24 corticosteroids were
made from solid compounds in 1 ug/ul concentrations diluting with methanol or
acetonitrile. These standards were diluted in methanol to make the working standards.
The working standard concentrations used are 0.01, 0.02, 0.05, 0.1, 0.5, 1.0, 10.0, and 20
ng/ul.
Calibration standard preparation: Drug-free animal urine was collected and pooled to
be processed into stripped urine. Stripped urine is urine which was taken through the
extraction process three times to eliminate any possible drugs in the urine from
endogenous or exonogeous sources. Ten microliters of a working standard are added to
one milliliter of stripped urine or plasma to make the calibration standards that have
concentrations of 0.1, 0.2, 0.5, 1.0, 5.0, 10, 100 and 200 ng/ml. After this point, standards
and samples are treated identically though the extraction process. Ten microliters of
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internal standard were added to the samples and standards before extraction. The standards
were extracted with the samples to assure uniformity in reagents and mixing times.
Extraction procedure: Caution MTBE is an extremely flammable liquid and vapor.
Vapor may cause a flash fire. MTBE can cause central nervous system depression and can
cause kidney and liver damage and tumors. Consult MSDS before using. Use in fume
hood with gloves and safety goggles (Fisher, 2007).
1. Adjust urine pH to 9.0 +/- 0.1 units. (Adjust plasma pH to 8.0 +/- 0.1 units.)
2. Pipette 1 ml of urine or plasma into a screw top tube.
3. Add ten microliters of 10 ng/ul internal standard solution.
4. Mix on rotorap for 10 min at 2 rpm.
5. Add 1 ml Type 1 H2O to tube. Vortex 10 sec.
6. Add 5 ml of Methyl-tert Butyl Ether (MTBE).
7. Rotorap for 10 min. at 2 rpm.
8. Centrifuge at 3000 rpm for 10 min.
9. Extract top MTBE layer using a Pasteur pipette. Dispense in tube (16mm x100mm).
10. Evaporate MTBE in turbovap at 46 C for 14 min.
11. Reconstitute in 100 ul of diluent. Sample is ready for analysis.
Instrumentation parameters: For working standards, 2 ul aliquots were injected. For
calibration standards and samples, 20 ul were injected which corrects for dilution since 1
ml of sample was concentrated to 0.1 ml. The HPLC gradient ramp is described in table 2.
Table 2. HPLC gradient with mobile phase composition gradient
Composition of mobile phase
gradient ramp
Time (min) Flow rate (ml/min) %A %B
0 0.6 70 30
4 0.6 70 30
12 0.6 50 50
16 0.6 5 95
20 0.6 5 95
21 0.6 70 30
25 0.6 70 30
25
Mass Spectrometer parameters
MS run time: 20 minutes
Other parameters are in table 3 on page 28.
Dexamethasone elimination study #1
Most dexamethasone treatment therapies call for 0.2 to 2 mg/kg as the initial dose
and additional doses of lower amounts over the next few days of treatment. An eight-year-
old male greyhound weighing 36 kg was orally dosed once with 0.1 mg/kg dexamethasone
(Sigma D9184-100mg Lot # 036k1031). Voluntary urine elimination samples were
collected pre-dosing and at 2, 4, 8, 24, 36, 48, 60, 72, 84 and 96 hours after dosing.
Food and water were available ad libitium to the greyhound. The test animal was
housed in a separate kennel to prevent carry over to other animals. Kennels are cleaned
daily.
Dexamethasone elimination study # 2:
Dexamethasone elimination study in equine urine administration sample #63. An
administration sample is a sample that was collected from an animal which had been
administered a known amount of a drug. In the equine study, 20 mg of dexamethasone
was dosed orally in two horses weighing 596 kg and 561 kg, ages unknown. Pre-dose
urine was collected by catheter. Post dose urine was collected by catheter at 2, 4, 8, 24, 48
hours. The drug administered was dexamethasone (Sigma Reference grade: D-1756, Lot
#87F-0740).
Fludrocortisone elimination study
An eight-year-old male greyhound weighing 35 kg was orally dosed once with five
0.1 mg fludrocortisone tablets (Barr Laboratories Lot # 6080391 exp. 8-31-08). Voluntary
urine elimination samples were collected pre-dosing and at 2, 4, 8, 24, 48, 72, and 96 hours




The HPLC gradient in table 2 on page 24 was used to determine retentions times
for the compounds in table 3. This gradient was optimized to prevent coeluting peaks as
much as possible. Diluted glucocorticoid standards were injected into the mass
spectrometer to optimize ionization parameters and analyte ions. The analyte ions are
presented in table 3 and the ionization parameters are presented in the table 4 on page 28.
Structures for these compounds are in the appendix starting on page 56.
Table 3. Ions and retention times (RT) using LC/MSn
Compound Mw Ionization and ions RT # RT(min)
triamacinolone 394.4 pos ms2 359, ions 359, 341, 339,321 1 3.04
fludocortisone
metabolite 384 pos ms2 384 ions 249,267,309 2 3.71
20 dihydro 6 alpha
methylprednisolone 376 neg ms3 421, 375 ions 357, 345, 327 3 4.65
hydrocortisone 362.5 pos ms2 363 ions (345, 327, 309, 267) 4 4.98
prednisolone 360.4
pos ms2 361.3 ions
265.3,279.3,289,307,325.2,343.1,362 5 5.16
fludrocortisone 380.5 pos 2 381 ions (295,313,333,349,361,381) 6 5.29
prednisone 358.4 pos ms2 359 ions (213.2,313.3,323.1,341) 7 5.39
cortisone 360.4 pos ms2 361.3 , ions( 163,307,325,341,343) 8 5.56
6 alpha
methylprednisolone 374.5 neg ms3 419, 343 ions 327, 309, 294 9 7.38
betamethasone 392.5
neg ms3 437, 361 ions 345, 327,310,325, 307,
292 10 7.82
flumethasone 410.5
neg ms 2 379 ions
290,305.1,325.1,328,343.1,363.1 11 7.88
dexamethasone 392.5 neg ms3 437, ms 361 ions 345, 325, 307,292 12 8.21
16 b methyprednisolone 372.5 neg ms2 341 ions 282.3,299.3,323.2,341.2 13 8.44
corticosterone 346.5 pos ms2 347.5 ions 269,293,311,329,347 14 9.44
beclomethasone 408.9
pos ms3 409, 391 ions
237,279,319,337.2,355.2,373.3 15 9.53
flurandrenolide 436.5
pos ms2 436.0 ions
303,315,331,359,361,377,417 16 10.04
fluocinolone (acetonide) 452.5 pos ms2 453 ions 337.1,341,413.2,433.1 17 10.44
triamacinolone
acetamide 434
pos ms 2 436 ions
321.2,339.2,357.1,393.3,397.2,415.2 18 10.72
fluorometholone 376.5 pos ms2 377.5 ions 279.2,321,339,357,377 19 10.72






Compound Mw Ionization and ions RT # RT(min)
deoxycorticosterone (21)
330.5 pos ms2 331 ions 331,313,295, 277, 267 22 13.93
medrysone 344.5 pos ms3 345,327 ions 309,291, 269, 225 23 14.95
flucinonide 494.5
pos ms2 495 ions
219.3,319.2,337.2,417.1,455,475 24 15.17
dichlorisone acetate 455.4 pos ms2 456 ions 253.1,319.2,337.2,397.2 25 15.28
amcinonide 502.6 pos ms2 503 ions 321.1,339,399.1,483.1 26 16.50
clobetasone butyrate 479 pos ms2 480 ions 389.2, 371,343, 317, 279 27 17.26
Tune parameters
Tune parameters are instrument parameters which when properly applied give
optimal results for an analyte. One analyte may be used to create a tune file for other
compounds. Tune parameters for triamicinolone were based on triamicinolone tune file.
For the other positive ion scans, the cortisone tune file was used. For the negative ions, the
two methyprednisolone tune files were used. Parameters common to all five tune files are
listed below.
Vaporizer temp: 430oC
Injection control parameters AGC settings: Full MS target 30000, SIM target 10000.0,
MSn Target10000.0, Zoom Target 3000.0
Other Tune parameters are in table 4 on page 28.
Scan segments: A scan segment is a user modifiable part of the analytical program that is
set for a particular retention time range. In this retention time range, ions are selected for
compounds that elute in the chosen time range. Since there are relatively few ions chosen
per scan segment, the detector scans the selected ions for a longer time period than would
be possible in full scan mode. This increased analysis time creates larger peak areas which
makes peak identification and quantification more exact.
The detector also spends practically no time on ions that are not listed in the scan
segment. This eliminates much of the noise that can mask analyte peaks for compounds at
low concentration levels. The details of the scan segments are listed on page 28.
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Table 4. Mass spectrometer tune parameters
parameter\tune file Triamcinolone MpredAPCI061306 Cortisone APCI
APCI source
Sheath gas Flow rate(arb) 50.00 55.00 45
Aux Gas Flow rate (arb) 5.00 5.00 5
Sweep Gas flow Rate (arb) 0.00 0.00 0
Discharge Current (uA) 5.00 5.00 5.00
Capillary Temp (oC) 275.00 275.00 275.00
Capillary Voltage (V) 7.00 -8.00 25.00
Tube Lens (V) 50.00 -65.00 80.00
Ion Optics
Multipole 00 offset(V) -4.25 3.50 -4.25
Intermultipole Lens 0 Volt.(V) -4.00 4.00 -4.00
Multipole 0 offset(V) -5.00 5.00 -5.25
Intermultipole Lens 1 Volt.(V) -15.00 12.00 -11.00
Gate LensVoltage (V) -64.00 68.00 -38.00
Multipole 1 offset(V) -11.50 14.00 -11.00
Multipole RF Amplitude (Vp-p) 400.00 400.00 400.00
Front Lens(V) -6.00 5.25 -6.25
parameter\tune file MpredAPCIFloAdj cortisoneAPCILOW
APCI source
Sheath gas Flow rate(arb) 50.00 45.00
Aux Gas Flow rate (arb) 5.00 5.00
Sweep Gas flow Rate (arb) 0.00 0.00
Discharge Current (uA) 5.00 5.00
Capillary Temp (oC) 275.00 275.00
Capillary Voltage (V) -41.00 25.00
Tube Lens (V) -65.00 80
Ion Optics
Multipole 00 offset(V) 4.00 -4.25
Intermultipole Lens 0 Volt.(V) 4.00 -4.00
Multipole 0 offset(V) 5.00 -5.25
Intermultipole Lens 1 Volt.(V) 8.00 -11.00
Gate LensVoltage (V) 46.00 0.00
Multipole 1 offset(V) 9.50 -11.00
Multipole RF Amplitude (Vp-p) 400.00 400.00
Front Lens(V) 5.00 -6.25
Scan segment details are listed below.
Segment 1: Duration = 4 min, number of scan events = 1,
tune method= triamcinaolone.
Scan event details 1 ITMS + c norm = (359.0) ->0 (95.0-500.0)
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MS/MS: CE 20 .0%, Q=0.25, time=30.0 Iso W= 2.0
Segment 2: Duration = 1 min, number of scan events = 1,
tune method=MpredAPCIFloAdj.
Scan event details 1 ITMS - c norm = (421.0) -> (375.0) ->0 (100.0-500.0)
MS2: CE 25 .0%, Q=0.25, time=30.0 Iso W= 2.0
MS3: CE 25 .0%, Q=0.25, time=30.0 Iso W= 2.0
Segment 3: Duration = 1.2 min, number of scan events = 4,
tune method= cortisoneAPCI.
Scan event details 1: ITMS + c norm = (381.0) ->o (100.0-500.0)
MS/MS: CE 25 .0%, Q=0.25, time=30.0 Iso W= 2.0
Scan event details 2: ITMS + c norm = (361.3) ->o (95.0-500.0)
MS/MS: CE 30 .0%, Q=0.25, time=30.0 Iso W= 2.0
Scan event details 3: ITMS + c norm = (3590) ->o (100.0-500.0)
MS/MS: CE 30 .0%, Q=0.25, time=30.0 Iso W= 2.0
Scan event details 4: ITMS + c norm = (363.5) ->o (100.0-500.0)
MS/MS: CE 30 .0%, Q=0.25, time=30.0 Iso W= 2.0
Segment 4: Duration = 2.8 min, number of scan events = 4,
tune method= MpredAPCI061306
Scan event details 1: ITMS - c norm = (437.0) -> (361) ->o (95.0-600)
MS2: CE 25 .0%, Q=0.25, time=30.0 Iso W= 2.0
MS3: CE 25 .0%, Q=0.25, time=30.0 Iso W= 2.0
Scan event details 2: ITMS - c norm = (419.0) -> (343.0) ->o (90.0-500.0)
MS2: CE 25.0%, Q=0.25, time=30.0 Iso W= 2.0
MS3: CE 25.0%, Q=0.25, time=30.0 Iso W= 2.0
Scan event details 3: ITMS - c norm = (379.0) ->o (100.0-600.0)
MS/MS: CE 25.0%, Q=0.25, time=30.0 Iso W= 2.0
Scan event details 4: ITMS - c norm = (341) ->o (100.0-600.0)
MS/MS: CE 30.0%, Q=0.25, time=30.0 Iso W= 2.0
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Segment 5: Duration = 1.0 min, number of scan events = 2,
tune method= cortisoneAPCI
Scan event details 1: ITMS + c norm = (347.5) ->o (95.0-500.0)
MS/MS: CE 25 .0%, Q=0.25, time=30.0 Iso W= 2.0
Scan event details 2: ITMS + c norm = (409.0) -> (391) ->o (105.0-500.0)
MS2: CE 30.0%, Q=0.25, time=30.0 Iso W= 5.0
MS3: CE 30.0%, Q=0.25, time=30.0 Iso W= 2.0
Segment 6: Duration = 2.0 min, number of scan events = 3,
tune method= cortisoneAPCI
Scan event details 1: ITMS + c norm = (436.0) ->o (120.0-500.0)
MS/MS: CE 25.0%, Q=0.25, time=30.0 Iso W= 4.0
Scan event details 2: ITMS + c norm = (409.0) -> (391) ->o (105.0-500.0)
MS/MS: CE 25.0%, Q=0.25, time=30.0 Iso W= 2.0
Scan event details 3: ITMS + c norm = (453.5) ->o (120.0-550.0)
MS/MS: CE 25.0%, Q=0.25, time=30.0 Iso W= 2.0
Segment 7: Duration = 1.75 min, number of scan events = 1,
tune method= cortisoneAPCI
Scan event details 1: ITMS + c norm = (435.0) ->o (115.0-500.0)
MS/MS: CE 25.0%, Q=0.25, time=30.0 Iso W= 2.0
Segment 8: Duration = 1.00 min, number of scan events = 1,
tune method= cortisoneAPCI
Scan event details 1: ITMS + c norm = (331.0) ->o (90.0-500.0)
MS/MS: CE 25.0%, Q=0.25, time=30.0 Iso W= 2.0
Segment 9: Duration = 1.25 min, number of scan events = 3,
tune method= cortisoneAPCI
Scan event details 1: ITMS + c norm = (345.0) -> (327.0) ->o (90.0-500.0)
MS2: CE 25.0%, Q=0.25, time=30.0 Iso W= 2.0
MS3: CE 25.0%, Q=0.25, time=30.0 Iso W= 2.0
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Scan event details 2: ITMS + c norm = (495.0) ->o (135.0-500.0)
MS/MS: CE 25.0%, Q=0.25, time=30.0 Iso W= 2.0
Scan event details 3: ITMS + c norm = (456.0) ->o (125.0-550.0)
MS/MS: CE 25.0%, Q=0.25, time=30.0 Iso W= 2.0
Segment 10: Duration = 1.00 min, number of scan events = 1,
tune method= cortisoneAPCI.
Scan event details 1: ITMS + c norm = (503.0) ->o (135-600.0)
MS/MS: CE 25.0%, Q=0.25, time=30.0 Iso W= 2.0
Segment 11: Duration = 2.50 min, number of scan events = 1,
tune method= cortisoneAPCI.
Scan event details 1: ITMS + c norm = (480.0) ->o (130-550.0)
MS/MS: CE 25.0%, Q=0.25, time=30.0 Iso W= 2.0
Segment 12: Duration = 0.50 min, number of scan events = 1,
tune method= cortisoneAPCILOW.
Scan event details 1: ITMS + c norm = (480.0) ->o (130-550.0)
MS/MS: CE 25.0%, Q=0.25, time=30.0 Iso W= 2.0
Using the LC gradient in table 2 and ions listed in table 3, the previously listed tune
parameters and scan segments, the chromatograph in figure 6 on page 32 is obtained for a
canine urine standard spiked at 100 ng/ml for the compounds listed in table 3 on page 26.
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Figure 6. Total Ion chromatograph of 100 ng/ml standard in canine urine.
Using the ion selection filters for cortisone and hydrocortisone, the chromatogram
presents a clearer picture of these two compounds in figure 7 on page 33.
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Figure 7. Ion chromatograph using filters for cortisone and hydrocortisone.
The mass spectra are presented with the ion chromatographs of cortisone and
hydrocortisone in figure 8 on page 34.
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Figure 8.  Ion chromatograph and mass spectra of cortisone and hydrocortisone
Figure 9 on page 35 contains the chromatograph and mass spectra of
dexamethasone and betamethasone. These chemicals have the same molecular formula
and are structurally identical except for a methyl group on c-16 that has an alpha
orientation in dexamethasone and a beta orientation in betamethasone as shown in figure 3
page 6.
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Figure 9.  Chromatograph and mass spectra of dexamethasone and
betamethasone.
The recoveries of dexamethasone, betamethasone, prednisolone, and dichlorisone
acetate for pH range from 5.0 to 10.0 in canine urine are shown in Table 5. The control
sample was the canine urine sample without pH adjustment.
Table 5. Extraction recoveries of select analytes in canine urine at various pH levels.
Sample Name % recovery
Matrix A B C D E
ph 5 3 2 50 4 18
control ph 6.2 4 3 41 7 16
ph 6.5 3 6 52 10 21
ph 7.0 9 8 62 16 26
ph 7.5 15 15 54 30 28
ph 8.0 18 31 55 49 35
ph 8.25 10 19 69 29 33
ph 8.50 6 10 54 16 23
ph 8.75 8 27 50 35 28
Legend: A=Prednisone, B=Dexamethasone and Betamethasone, C= Dichlorisone acetate
D= summation of recoveries for the dexamethasone betamethasone coelution and prednisolone
E= Average recoveries for the dexamethasone betamethasone coelution and prednisolone
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Table 5. (continued )
Sample Name % recovery
Matrix A B C D E
ph 8.75 8 27 50 35 28
ph 9.0 17 36 57 53 37
ph 9.25 7 30 56 37 31
ph 9.50 0 26 34 26 20
ph 9.75 3 14 46 17 21
ph 10.0 8 20 42 28 23
ph 9 w h20 13 39 65 53 39
pH 9 w h20 and 7 ml. MTBE 11 31 64 42 35
ph 9.0 duplicate 9 32 62 41 34
9ml with 1 ml naso4 extracted 1 ml urine 8 36 67 44 37
Table 6 summarizes the average analyte recoveries and linear correlation
coefficient (r2) of the standards used in the standard curve for canine urine. The r2 value
range is 0-1 with a value of exactly 1 indicating an ideal linear relationship between the
parameters in the calculation. The calibration curves in this study are calculated using a
linear equation. The origin is ignored as opposed to being included in the calculation or
using a forced zero equation. The calibration curves are not weighted so that each
calibration point has the same amount of influence on the calibration curve calculation as
any other point. The analyses summarized in this table were performed after the mass
spectrometer had been optimized for each analyte. The analyses in table 5 were performed
prior to mass spectrometer optimization.




triamicinalone methyprednisolone hydrocortisone fludrocortisone
R2 = 0.9994 R2 = 0.9975 R2 = 1.0000 R2 = 1.0000
% recovery =




R2 = 0.9974 R2 = 0.9998 R2 = 0.9997 R2 = 0.9984
% recovery =
72. % recovery = 62. % recovery = 65. % recovery = 73.
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Table 6 continued.
betamethasone flumethasone dexamethasone 16 beta methylprednisolone
R2 = 0.9922 R2 = 0.9991 R2 = 0.9994 R2 = 0.9998
% recovery= 70. % recovery = 67. % recovery = 88. % recovery = 75.
corticosterone beclomethasone flurandrenolide fluocinilone acetamide
R2 = 0.9999 R2 = 1.0000 R2 = 1.0000 R2 = 0.9996
% recovery= 82. % recovery = 79. % recovery = 75. % recovery = 95.
triamicinolone_
acetamide fluorometholone paramethasone_ acetate deoxycorticosterone
R2 = 1.0000 R2 = 0.9998 R2 = 1.0000 R2 = 0.9999
% recovery= 94. % recovery = 89. % recovery = 105. % recovery =100.
medrysone flucinonide amcinonide clobetasone_butyrate
R2 = 0.9999 R2 = 0.9999 R2 = 0.9965 R2 = 0.9974
%recovery
=104. % recovery = 98. % recovery =103. % recovery= 112.
* Recoveries are +/- 5%.
Equine plasma was also optimized for pH. In this later experiment, all 24 analytes
were used to obtain the optimal pH using a standard to simulate 100 ng/ml of each analyte.
The results are included in table 7.
Table 7. Extraction recoveries of select analytes in stripped equine plasma at varying




7.5 151 71 15 30
8.0 130 83 91 81
8.5 108 67 99 85
9.0 138 69 95 85
9.5 90 78 89 79
pH fludrocortisone prednisone cortisone 6_alpha_methylprednisolone
7.5 84 53 69 83
8.0 81 79 89 88
8.5 90 38 91 83
9.0 84 81 79 92
9.5 81 40 67 83
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Table 7 (continued)
pH betamethasone flumethasone dexamethasone 16beta-methylprednisolone
7.5 103 100 85 83
8.0 88 105 85 85
8.5 100 106 82 80
9.0 109 99 90 85
9.5 102 98 88 85
pH corticosterone beclomethasone flurandrenolide fluocinilone_acetamide
7.5 82 97 90 107
8.0 85 89 96 104
8.5 88 98 90 97
9.0 89 87 98 109
9.5 85 77 102 111
pH fluorometholone triamicinolone_acetamide paramethasone_acetate deoxycorticosterone
7.5 103 99 92 115
8.0 102 102 99 122
8.5 95 95 99 103
9.0 106 102 100 121
9.5 110 105 90 100
pH medrysone flucinonide dichlorisone_acetate amcinonide
7.5 136 124 100 68
8.0 128 107 119 123
8.5 106 97 103 123
9.0 124 110 93 141







Figures 10-12 on pages 39-40 show the recoveries of the glucocorticoids studied in
this method. All of the percent recoveries represented in the figures were from samples
spiked with 100 ng/ml of the analytes. These samples were extracted and analyzed in the
same run. The compounds are separated into three graphs to make the data more legible.
The first set of analytes is the set of analytes with the shortest retention times. The second
set of compounds contains the next set of compounds based on retention time. The third
set contains the compounds with the longest retention times.
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Figure 10. pH vs. drug recovery for first set of analytes (100 ng/ml) in equine plasma.




























Figure 11. pH vs. drug recovery for second set of analytes (100 ng/ml) in equine
plasma.
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Figure 12. pH vs. drug recovery for third set of analytes (100 ng/ml) in equine
plasma.
An example of a calibration curve is presented in figure 13. This particular calibration
curve was produced using dexamethasone standards made from stripped canine urine.
Extracted dexamethasone curve

















Figure 13. Extracted dexamethasone calibration curve in canine urine.
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Each analyte in a study should produce a calibration curve similar to figure 13.
Table 8 contains the volume and pH values of canine urine in the dexamethasone
elimination study.
Table 8. Canine urine volume and pH value in dexamethasone study.
Hours Post Dose Volume of Urine collected (ml) initial pH Final adjusted pH
0 20 5.83 9.05
2 54 6.14 9.03
4 17 8.47 9.04
8 128 7.9 9.08
24 104 6.53 9.07
36 30 6.06 9.02
48 78 5.74 9.06
60 36 6.39 9.08
72 66 6.8 9.06
84 77 7.31 9.05
96 18 5.95 9.05
The results in table 9 on page 42 are from three sets of extracted canine urine
samples from the dexamethasone elimination study. The first two data sets were re-
extracted from urines that had the sample pH adjusted to 9.0 +/- 0.1 six weeks prior to the
extraction. These samples were originally extracted shortly after the pH adjustment but
due to instrument malfunction on a few runs, the volume of several extracted samples was
depleted. The third set of samples were stored at the original pH, extracted after pH
adjustment, and analyzed after the instrument had been repaired. There is no result for
T=0 for the third set as the original urine sample had been depleted.
The first two sets were extracted in the same run as the third set. It is speculated
that sample degradation occurred due to storage at pH 9. Degradation studies were not
performed on the samples. Extracts (ex) 32 and 33 were extracted using the current in
house method using 9 ml of sample and extracted with ethyl acetate. The concentration
was corrected to compare to using 1 ml of sample.
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Table 9. Dexamethasone in canine urine results
Dexamethasone Equation Y = 0.00440369+0.0100207*X R2 = 0.9996
Dexamethasone internal
Sample Name Calc Amount Area standard Area RT(min.)
ex 1 blank 11-30 stripped urine N/F 641384.
ex 2 0.1ng/ml mix 24 11-30 stripped urine < 1 538. 636221. 8.42
ex 3 0.2 ng/ml mix 24 11-30 stripped urine < 1 1195. 606411. 8.44
ex 4 .5 ng/ml mix 24 11-30 stripped urine < 1 3272. 563529. 8.54
ex 5 1.0 ng/ml mix 24 11-30 stripped urine < 1 7404. 603559. 8.58
ex 6 5.0 ng/ml mix 24 11-30 stripped urine 5. 22767. 413061. 8.42
ex 7 10 ng/ml mix 24 11-30 stripped urine 10. 35660. 352018. 8.46
ex 8 100 ng/ml mix 24 11-30 stripped urine 103. 422065. 405430. 8.45
ex 9 200 ng/ml mix 24 11-30 stripped urine 198. 861041. 432372. 8.46
ex 10 t=0 urine first set N/F 422180.
ex 11 t=2 hr 101. 155045. 152227. 8.44
ex 12 t=4hr 46. 180638. 387321. 8.46
ex 13 t=8hr 40. 146295. 360749. 8.46
ex 14 t=24 15. 71385. 471358. 8.48
ex 15 t=36 4. 20248. 411233. 8.46
ex 16 t=48 < 1 3936. 376144. 8.46
ex 17 t=60 < 1 1407. 365458. 8.44
ex 18 t=72 < 1 415. 403574. 8.50
ex 19 t = 84 < 1 535. 408240. 8.46
ex 20 t =96 < 1 196. 384888. 8.46
ex 21 t=0 second set N/F 466435.
ex 22 t=2 97. 251434. 256773. 8.44
ex 23 t=4 50. 200074. 396759. 8.44
ex 24 t=8 51 122942. 240484. 8.44
ex 25 t=24 16. 70758. 443015. 8.46
ex 26 t=36 5. 20003. 381294. 8.48
ex 27 t=48 < 1 4251. 403897. 8.42
ex 28 t=60 < 1 615. 320896. 8.48
ex 29 t=72 < 1 1038. 434722. 8.38
ex 30 t=84 < 1 553. 456711. 8.44
ex 31 t=96 < 1 318. 504732. 8.46
ex 32 steroid ex t=8 43. 1034232. 264576. 8.44
ex 33 steroid ex t=48 < 1 13590. 132916. 8.43
ex 34 ph t=2 third set 129. 275360. 212018. 8.46
ex 35 ph t=4 55. 247675. 442203. 8.46
ex 36 ph t=8 58. 238456. 410197. 8.44
ex 37 ph t=24 23. 89049. 384433. 8.46
ex 38 ph t=36 6. 19938. 305767. 8.46
ex 39 ph t=48 < 1 5874. 411052. 8.48
ex 40 ph t=60 < 1 1280. 305325. 8.48
ex 41 ph t=72 < 1 1109. 369995. 8.48
ex 42 ph t=84 < 1 443. 405181. 8.46
ex 43 ph t=96 < 1 309. 536835. 8.54
ex 44 blank N/F 490099.
Average internal standard area= 406577.
Note RT = retention time for the analyte, not the internal standard.
Average dexamethasone retention time (min.) = 8.46. Standard deviation= 0.034
NF= Peak Not Found
.
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The area counts for dexamethasone in canine urine are plotted against the hours




















Figure 14. Dexamethasone elimination study area counts vs. hours post dose
Figure 15 illustrates the area counts of the latter part of the elimination study on a
smaller scale.




















Figure 15. Dexamethasone elimination study results last 48 hours on smaller scale
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Figure 16. Dexamethasone elimination study concentrations vs. hours post dose
Tables 10-12 summarize the hydrocortisone, cortisone and dexamethasone
concentrations in the dexamethasone equine urine elimination study.
Table 10. Hydrocortisone in equine urine dexamethasone study
Hydrocortisone







blank stripped urine 1-2-07 < 1 3104. 503282. 5.11
0.1 ng/ml mix 24 1-2 stripped urine < 1 4464. 543407. 5.16
0.2 ng/ml mix 24 1-2 stripped urine < 1 4413. 440830. 5.22
0.5 ng/ml mix 24 1-2 stripped urine < 1 9059. 488035. 5.13
1.0 ng/ml mix 24 1-2 stripped urine 1. 13639. 382978. 5.16
5.0 ng/ml mix 24 1-2 stripped urine 5. 65724. 441449. 5.16
10.0 ng/ml mix 24 1-2 stripped urine 10. 114183. 432052. 5.15
100 ng/ml mix 24 1-2 stripped urine 100. 1162568. 451378. 5.17
0 hr a63 1-2 15. 185016. 462209. 5.16
2hr a63 1-2 17. 196463. 433068. 5.16
4hr a63 1-2 8. 94020. 466255. 5.14
8 hr a63 1-2 3. 37645. 474876. 5.13
24 hr a63 1-2 < 1 11144. 466664. 5.16
48 hr a63 1-2 21. 258915. 481614. 5.20
0 hr a63 1-2 dup 17. 187814. 417141. 5.22








4hr a63 1-2 dup 11. 116098. 411359. 5.23
8 hr a63 1-2 dup 3. 36649. 428728. 5.20
24 hr a63 1-2 dup < 1 10805. 410182. 5.15
48 hr a63 1-2 dup 25. 277768. 427757. 5.15
Table 11. Cortisone in equine urine dexamethasone study
Cortisone







blank stripped urine 1-2-07 N/F 503282.
0.1 ng/ml mix 24 1-2 stripped urine N/F 543407.
0.2 ng/ml mix 24 1-2 stripped urine N/F 440830.
0.5 ng/ml mix 24 1-2 stripped urine < 1 3238. 488035. 5.73
1.0 ng/ml mix 24 1-2 stripped urine < 1 4862. 382978. 5.73
5.0 ng/ml mix 24 1-2 stripped urine 5. 24366. 441449. 5.72
10.0 ng/ml mix 24 1-2 stripped urine 11. 45058. 432052. 5.72
100 ng/ml mix 24 1-2 stripped urine 100. 411117. 451378. 5.71
0 hr a63 1-2 11. 51214. 462209. 5.77
2hr a63 1-2 14 56510. 433068. 5.70
4hr a63 1-2 6. 29442. 466255. 5.72
8 hr a63 1-2 3. 14591. 474876. 5.72
24 hr a63 1-2 N/F 10631. 466664.
48 hr a63 1-2 17 76543. 481614. 5.75
0 hr a63 1-2 dup 13. 52635. 417141. 5.79
2hr a63 1-2 dup 11. 46277. 449517. 5.84
4hr a63 1-2 dup 9. 38197. 411359. 5.79
8 hr a63 1-2 dup 2. 12556. 428728. 5.77
24 hr a63 1-2 dup 2. 9880. 410182. 5.72
48 hr a63 1-2 dup 22. 89330. 427757. 5.73
Table 12. Dexamethasone in equine urine study
Dexamethasone
Y = 0.00453013+0.00854919*X R2 = 0.9994
Sample Name Calculated concentration(ng/ml) Analyte Area Internal standard Area RT(min.)
solvent N/A 18. ?? 8.42
blank stripped urine 1-2-07 N/F 503282.
0.1 ng/ml mix 24 1-2 stripped urine < 1 256. 543407. 8.38
0.2 ng/ml mix 24 1-2 stripped urine < 1 449. 440830. 8.38
0.5 ng/ml mix 24 1-2 stripped urine < 1 1849. 488035. 8.42
1.0 ng/ml mix 24 1-2 stripped urine < 1 3485. 382978. 8.38
5.0 ng/ml mix 24 1-2 stripped urine 6. 22845. 441449. 8.38
10.0 ng/ml mix 24 1-2 stripped urine 12. 45996. 432052. 8.40
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Table 12 continued.
100 ng/ml mix 24 1-2 stripped urine 100. 387130. 451378. 8.41
0 hr a63 1-2 N/F 462209.
2hr a63 1-2 18. 66786. 433068. 8.40
4hr a63 1-2 30. 120077. 466255. 8.40
8 hr a63 1-2 13. 53058. 474876. 8.38
24 hr a63 1-2 1. 7385. 466664. 8.42
48 hr a63 1-2 < 1 146. 481614. 8.40
0 hr a63 1-2 dup N/F 417141.
2hr a63 1-2 dup 14. 57472. 449517. 8.52
4hr a63 1-2 dup 37. 132964. 411359. 8.50
8 hr a63 1-2 dup 16. 59182. 428728. 8.42
24 hr a63 1-2 dup 1. 6184. 410182. 8.42
48 hr a63 1-2 dup <1 123. 427757. 8.44
Figures 17 -19 are graphical depictions of the data presented in tables 10-12.
Hydrocortisone concentration post























Figure 17. Hydrocortisone concentration in equine dexamethasone study.
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Figure 18. Cortisone concentration in dexamethasone equine urine study



















Figure 19. Dexamethasone concentration in dexamethasone equine urine
study.
The increased dexamethasone concentration in figure 20 on page 48 corresponds to
decreased hydrocortisone and cortisone concentrations. The concentrations of these
48
compounds return to a level higher than the original baseline values after the
dexamethasone has been eliminated. This effect was published by Toutain in 1984.


















Figure 20. Comparison of dexamethasone concentration to cortisone and
hydrocortisone
Table 13 contains the data used for the calibration curves for fludrocortisone,
hydrocortisone and cortisone in the fludrocortisone elimination study in canine urine.
Table 13. Calibration curve in fludrocortisone canine urine study
Fludrocortisone elimination study (standards are in stripped urine matrix)
fludrocortisone hydrocortisone Cortisone








blank N/F N/F N/F
0.1 ng/ml 1. 270. N/F N/F
0.2 ng/ml 1. 412. N/F N/F
0.5 ng/ml 1. 1973. N/F 3. 2465.
1.0 ng/ml 3. 3856. 3. 7362. 4. 3115.
5.0 ng/ml 6. 27674. 7. 58964. 7. 21355.
10.0 ng/ml 9. 43537. 10. 91594. 9. 30202.
100 ng/ml 92. 554509. 93. 1140799. 88. 395540.
200 ng/ml 204. 1257801. 204. 2589343. 206. 959560.
Tables 14 -16 on page 49 contain data from the fludrocortisone elimination study in
canine urine. The different run numbers are replicates of the same samples extracted and
analyzed at the same time.
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Table 14. Fludrocortisone for runs 1-3 in canine urine
Fludrocortisone (ng/ml)
hours post dose run 1 run 2 run 3
0 N/F N/F N/F
2 3. 3. 4.
4 7. 8. 8.
8 5. 6. 5.
24 N/F 1. N/F
48 N/F N/F N/F
72 N/F N/F N/F
96 N/F N/F N/F
Table 15. Hydrocortisone in fludrocortisone canine urine study
Hydrocortisone (ng/ml)
hours post dose run 1 run 2 run 3
0 9. 9. 8.
2 6. 7. 12.
4 5. 6. 6.
8 3. 4. 3.
24 7. 7. 7.
48 9. 9. 11.
72 13. 12. 13.
96 7. 7. 8.
Table 16. Cortisone in fludrocortisone canine urine study
Cortisone (ng/ml)
hours post dose run 1 run 2 run 3
0 13. 14. 13.
2 9. 10. 16.
4 7. 8. 7.
8 5. 5. 5.
24 8. 8. 8.
48 10. 10. 12.
72 13. 12. 13.
96 8. 8. 9.
Fludrocortisone metabolite
After the initial LC/MSn run of the fludrocortisone samples, the samples were analyzed
for metabolites. One metabolite was discovered at a retention time of 3.73 minutes and
m/z 384. The base peak for this compound is m/z 267.25. Other ions used for
qualification and quantification were m/z 249 and 309. The chromatograph and mass
spectra of the fludrocortisone metabolite are in figure 21 on page 50.
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Figure 21. Chromatograph and mass spectra of fludrocortisone metabolite
Table 17 illustrates the fludrocortisone metabolite areas and signal to noise (S/N)
ratio in the canine urine study
Table 17. Fludrocortisone metabolite areas in canine urine
Sample Name Area S/N
solvent N/F
0 hr N/F
2 hr 4323. 6.67
4 hr 18479. 37.94
8 hr 19858. 32.23
24 hr N/F
Figure 22 on page 51 is a side-by-side comparison of the chromatographs of
fludrocortisone and its metabolite.
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Figure 22. Chromatographs of fludrocortisone and metabolite
Figure 23 is the chemical structure of fludrocortisone.
Figure 23. Chemical structure of fludrocortisone (Merck, 2001)
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The structure in figure 24 was proposed after examination of mass spectra and
possible metabolite routes described in Gower (1984). The name for the proposed
fludrocortisone metabolite in figure 24 is 9-alpha -fluoro-3, 11-beta, 17-alpha, 20, 21 –
pentahydroxy- 4- pregnene.
Figure 24. Proposed chemical structure of fludrocortisone metabolite
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CHAPTER 5. SUMMARY AND INTERPRETATION
This research presents refined extraction and analytical techniques to identify and
quantify 24 corticosteroids in canine urine and equine plasma and urine. The pure single
compound analyte standards were injected into the mass spectrometer to optimize mass
spectrometer operating parameters for the compounds. These parameters were used to
determine the ions selected for identification and quantification.
The LC gradient was optimized to prevent co-elution of chromatographic peaks.
Using this gradient, retention times for the analytes were determined. The combination of
retention times and mass spectra ions enabled a LC/MSn analytical method to be created to
determine the efficiency of the extraction process.
A liquid/liquid extraction process was used with 1 ml of sample and MTBE as the
extractant. The initial pH study in canine urine provided evidence that the addition of 1 ml
of type 1 water with a sample pH of 9 +/- 0.1 pH units produced the best average yield for
all of the analytes compared to extractions using other pH values. Average recoveries for
standards from 0.5 - 200 ng/ml ranged from 41% for triamicinolone to 112% for
clobetasone butyrate. With the exception of triamacinolone and 20-dihydro-6-alpha
methylprednisolone, recoveries were 60 % or higher. The lowest correlation coefficient for
the 24 analyte standard curves was 0.9922.
The equine plasma pH study was performed using a pH range from 7.0 to 9.5. The
results using a sample pH of 8.0 +/-0.1 pH unit yielded optimal glucocorticoid recoveries.
Average recoveries for standards ranged from 63% for prednisone to 114% for clobetasone
butyrate. The lowest r2 in the plasma samples was 0.9709.
The dexamethasone elimination study in the canine demonstrated the practical use of
this method. The calibration was performed using a stripped urine matrix spiked with the
analytes. The study showed detection of dexamethasone to 48 hours post dose. This
experiment also produced recoveries similar to the current in-house method. The method
used in this research requires 1 ml of sample instead of 9 ml required for the in-house
extraction procedure. This small amount of required sample allows testing of spikes and
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duplicates using much less sample than required by other methods. The small sample size
is also useful if the collected sample has low volume or if other analytical tests are required
for the sample.
The study of dexamethasone in equine urine produced good recoveries for
dexamethasone. The results of this study also demonstrated similar hydrocortisone
suppression as had been cited from Toutain (1984). This study detected dexamethasone to
24 hours post dose. The hydrocortisone and cortisone concentrations remained depressed
into the 24-48 hour time period. This study used a dexamethasone dose of 33 ug/kg. The
Toutain study used 50 ug/kg, which explains the increased length of cortisol suppression in
the Toutain study compared to this study.
The canine fludrocortisone study also produced hydrocortisone suppression. The
hydrocortisone concentration in the urine returned to time = 0 concentrations after 24-48
hours. The cortisone concentration returned to time = 0 concentration between 48-72
hours.
All three extraction runs detected fludrocortisone for 2, 4 and 8 hours post dose. One
extraction run detected fludrocortisone at 24 hours post dose. The fludrocortisone study
also produced a metabolite, which was detected in the 2, 4 and 8-hour post dose samples.
The metabolite area counts had approximately the same area counts as the peaks for the
unmetabolized eliminated fludrocortisone. The retention time of the metabolite is 3.72
minutes compared to 5.61 minutes for fludrocortisone. This metabolite had m/z of 384.
The molecular formula for the metabolite named 9-alpha -fluoro-3, 11-beta, 17-alpha, 20,
21 – pentahydroxy- 4- pregnene is C21H33FO5.
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CHAPTER 6. CONCLUSIONS
This report presents evidence of the effectiveness of this method for the analysis of
glucocorticoids in different matrices. The majority of the work was on the analysis of
glucocorticoids in canine urine due to subject availability and ease of sample collection.
Recoveries of glucocorticoids using different extraction pHs were tested to obtain an
optimal extraction pH of 9 for urine. Studies were also presented which varied the solvent
to sample ratio from the final 5:1 ratio.
Studies also were performed on equine plasma samples. The optimal extraction pH
was discovered using a pH range similar to that used for canine urine. The optimal pH for
equine plasma for this technique is pH 8.
The glucocorticoid elimination studies in the canine and equine test subjects
demonstrated a drug elimination pattern similar to what had been previously observed in
the literature. These studies also produced cortisone and hydrocortisone suppression
which had been demonstrated previously (Toutain, 1984). The fludrocortisone study
produced an elimination pattern similar to other glucocorticoid studies and a metabolite,
which had not been discussed in previous canine urine studies.
The extraction and analytical techniques presented in this research requires only a
small amount of sample to be as effective as other methods requiring larger amounts of
samples. The technique identifies and quantifies 24 glucocorticoids in a single analytical
run in plasma and urine. This analysis should decrease cost of analysis and increase
laboratory throughput due to time savings.
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APPENDIX: COMPOUND STRUCTURES
Figure 25. Structures of amcinonide through cortisone (Merck, 2001)
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Figure 26. Structures of deoxycorticosterone to flumethasone (Merck, 2001)
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Figure 27. Structures of fluocinolone acetamide to medrysone (Merck, 2001)
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Figure 28. Structures of methyprednisolone to prednisone (Merck, 2001)
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Figure 27. Structures of triamicinolone and triamicinolone acetamide
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